dapagliflozin + sitagliptin (AstraZeneca)

This reference drug entity represents the co-administration of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin and the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin. In the context of clinical development by Chong Kun Dang Pharmaceutical, this combination (referred to by the internal codes D759 and D308) serves as the reference comparator in Phase 1 pharmacokinetic and safety studies for the fixed-dose combination product CKD-389. Dapagliflozin reduces renal glucose reabsorption, leading to urinary glucose excretion, while sitagliptin increases the levels of active incretin hormones, enhancing insulin secretion and decreasing glucagon levels. Both components are established, orally administered treatments for type 2 diabetes mellitus, providing complementary glycemic control through renal and incretin-based pathways.

Brand names

FarxigaJanuviaForxiga

Other names

dapagliflozin and sitagliptin co-administration